Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec;63(1-3):58-69.
doi: 10.1007/s12026-015-8719-0.

Advancing drug delivery systems for the treatment of multiple sclerosis

Inna Tabansky  1 , Mark D Messina  2   3 , Catherine Bangeranye  3 , Jeffrey Goldstein  2   3 , Karen M Blitz-Shabbir  2 , Suly Machado  2   3 , Venkatesh Jeganathan  4 , Paul Wright  2 , Souhel Najjar  2 , Yonghao Cao  4 , Warren Sands  5   6 , Derin B Keskin  7 , Joel N H Stern  8   9   10   11
Affiliations
Review

Advancing drug delivery systems for the treatment of multiple sclerosis

Inna Tabansky et al. Immunol Res. 2015 Dec.

Erratum in

Abstract

Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system. It is characterized by demyelination of neurons and loss of neuronal axons and oligodendrocytes. In MS, auto-reactive T cells and B cells cross the blood-brain barrier (BBB), causing perivenous demyelinating lesions that form multiple discrete inflammatory demyelinated plaques located primarily in the white matter. In chronic MS, cortical demyelination and progressive axonal transections develop. Treatment for MS can be stratified into disease-modifying therapies (DMTs) and symptomatic therapy. DMTs aim to decrease circulating immune cells or to prevent these cells from crossing the BBB and reduce the inflammatory response. There are currently 10 DMTs approved for the relapsing forms of MS; these vary with regard to their efficacy, route and frequency of administration, adverse effects, and toxicity profile. Better drug delivery systems are being developed in order to decrease adverse effects, increase drug efficacy, and increase patient compliance through the direct targeting of pathologic cells. Here, we address the uses and benefits of advanced drug delivery systems, including nanoparticles, microparticles, fusion antibodies, and liposomal formulations. By altering the properties of therapeutic particles and enhancing targeting, breakthrough drug delivery technologies potentially applicable to multiple disease treatments may rapidly emerge.

Keywords: Drug delivery systems; Fusion antibodies; Microparticles; Multiple sclerosis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Clin Oncol. 2001 Jul 15;19(14):3312-22 - PubMed
    1. J Pharm Sci. 2006 May;95(5):1060-74 - PubMed
    1. ACS Nano. 2014 Mar 25;8(3):2148-60 - PubMed
    1. Nat Med. 2005 Mar;11(3):328-34 - PubMed
    1. Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20918-23 - PubMed

Publication types

MeSH terms

LinkOut - more resources